| Autor: |
E, Kabícková, P, Kavan, J, Koutecký, J, Malis, J, Stanková, P, Gajdos, R, Kodet, E, Cumlivská |
| Jazyk: |
čeština |
| Rok vydání: |
2001 |
| Předmět: |
|
| Zdroj: |
Casopis lekaru ceskych. 139(20) |
| ISSN: |
0008-7335 |
| Popis: |
Children with primary refractory or recurrent malignant lymphoma have usually poor prognosis. Less than 10% of those, who were treated with conventional-dose regimens had survived for 2 years. In an attempt to improve the outcome for these patients, we explored the role of consolidation high-dose chemotherapy with autografting.Forty-five patients with poor-prognosis lymphoma, of whom 27 were males, underwent megatherapy between January 1992 and December 1999. High-dose chemotherapy was indicated in patients with poor initial response to first-line chemotherapy (14 cases) or in the relapse (31 cases). The group consisted of 27 patients with Hodgkin's disease and 18 patients with non-Hodgkin's lymphoma. The median age was 14.7 years. The conditioning for Hodgkin's disease patients contained cyclophosphamide, etoposide and busulfan or carmustine. Patients with non-Hodgkin's lymphomas received cyclophosphamide, etoposide and busulfan or total body irradiation. Bone marrow was used as the source of haemopoietic stem cells in ten patients, peripheral blood in twenty-eight, and both sources were used in seven patients. After the median follow-up of 47 months, the final survival was 61%. Eleven patients died of the disease progression, four of the infectious complications, one at a car accident. Median time to relapse after the transplantation was 7.5 months.Further improvement of these results will require earlier transplantation, improved preparative regiments or early posttransplant immunotherapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
